Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology
Abstract
Comorbidity with metabolic diseases indicates that lipid metabolism plays a role in the etiology of Alzheimer's disease (AD). Comprehensive lipidomic analysis can provide new insights into the altered lipid metabolism in AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1016/j.dadm.2019.07.002
Entities
People
- Alzheimer Disease Metabolomics Consortium
- Andrew J. Saykin
- Dinesh Kumar Barupal
- Kwangsik Nho
- Matthias Arnold
- Oliver Fiehn
- Peter J. Meikle
- Rebecca Baillie
- Rima Kaddurah‐daouk
- Sili Fan
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- Baker IDI Heart and Diabetes Institute
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Duke University
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Helmholtz Zentrum München
- Hoffmann-La Roche
- Indiana University
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, Davis